Get started
Author

Lucía Regales

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
2009 · Lucia Regales, Yixuan Gong, et al. · Journal of Clinical Investigation · 369
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
2009 · Martin L. Sos, Stefanie Fischer, et al. · Proceedings of the National Academy of Sciences · 254
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
2007 · Lucia Regales, Marissa N. Balak, et al. · PLoS ONE · 125
PDF
Identification and Functional Validation of a 5′ Upstream Regulatory Sequence in the Human Tyrosinase Gene Homologous to the Locus Control Region of the Mouse Tyrosinase Gene
2003 · Lucía Regales, Patricia Giraldo, et al. · Pigment Cell Research · 37
Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M
2014 · Shigeru Kawabata, José R. Mercado-Matos, et al. · Cell Reports · 30
PDF
Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone
2015 · Shigeru Kawabata, M. Christine Hollander, et al. · Oncotarget · 15
PDF
Design of vectors for transgene expression: The use of genomic comparative approaches
2008 · Lluís Montoliu, Rosa Roy, et al. · Comparative Immunology Microbiology and Infectious Diseases · 10
Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Christian Grommes, Han Tun, et al. · Blood · 5
PDF
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
2024 · Christian Grommes, Han W. Tun, et al. · Journal of Clinical Oncology · 2
Cdc7 inhibition as a novel approach for pancreas cancer therapy.
2013 · Mark G. Frattini, Lucia Regales, et al. · Journal of Clinical Oncology · 2
Abstract 2153: Cdc7 Inhibition as a novel approach for pancreas cancer therapy.
2013 · Lucia Regales, Ruth Santos, et al. · Cancer Research · 1
Prognostic Factors and Treatment Effect Modifier Candidates in Advanced HER2-Mutant NSCLC: A Targeted Literature Review
2026 · Anne-Mary Lewis-Mikhael, Xuan Wang, et al. · Preprints.org
Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma
2023 · Christian Grommes, Grzegorz S. Nowakowski, et al. · Blood
PDF
Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M
2011 · Shigeru Kawabata, M. Christine Hollander, et al. · Cancer Research
Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib
2011 · Shigeru Kawabata, Jose Mercado, et al. · Cancer Research
Abstract 4689: Inhibition of IL-6/Jak/Stat3 signaling: a novel and potent targeting therapy for lung cancer
2011 · Sizhi P. Gao, Ninghui Mao, et al. · Cancer Research
IL-22 The mouse tyrosinase gene: structural and functional studies in transgenic mice
2003 · P. Giraldo, L. Regales, et al. · Pigment Cell Research
Works count: 17
Citation count: 850
H-index: 7
I10-index: 7
Year
Topic
Type